Mizuho raised the firm’s price target on Quest Diagnostics (DGX) to $174 from $160 and keeps an Outperform rating on the shares. The firm increased estimates citing the company’s following good Q3 results and solid initial 2025 outlook. Quest’s earnings visibility remains high given solid underlying healthcare utilization trends, market share gains and solid mix, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DGX:
- Snap upgraded, McDonald’s downgraded: Wall Street’s top analyst calls
- Quest Diagnostics awarded several contracts by CDC
- Quest Diagnostics price target raised to $185 from $165 at Citi
- Quest Diagnostics price target raised to $168 from $154 at Barclays
- Quest Diagnostics upgraded to Outperform from Neutral at Baird